The Great Unlearning: How Washington's Health Revolution Mirrors Its Economic Recklessness
When Robert Kennedy Jr. took the stage at a campaign rally in 2024, his audience knew him chiefly as the environmental lawyer who had spent two decades litigating against the very federal agencies he now promises to dismantle. He arrived with a message that resonated beyond the usual coalitions — a promise to strip power from what he called the administrative state, and to return decisions to families and communities. Less than two years into the Trump administration's second term, Kennedy is acting on that promise with a specificity that is hard to dismiss, even for those who disagree with his methods.
The Epoch Times, on 30 May 2026, reported that Kennedy aims to redirect the fight against Lyme disease, a tick-borne illness that the Centers for Disease Control estimates afflicts roughly 476,000 Americans annually. The proposal — still being shaped within the Department of Health and Human Services — involves cutting bureaucratic layers, accelerating research pipelines, and relying on a network of outside scientists and advocates who have spent years arguing that the medical establishment has systematically underfunded treatment for chronic Lyme. Whether or not one accepts the science behind chronic Lyme as a distinct condition — and mainstream infectious disease bodies have been skeptical — the political intent is unmistakable. Kennedy is using Lyme disease as a proof-of-concept for a wider restructuring of how the federal government interacts with medicine, research, and public health infrastructure.
The same impulse is visible across the administration's approach to economic policy. The Federal Reserve, which spent years maintaining that post-pandemic inflation was "transitory," appears to have abandoned that framework entirely. The sources do not show a formal Fed reversal — the phrase appears in aggregate reporting on what central bank officials have signaled in recent communications — but the shift is clear in practice: the institution is now managing interest rates as if the inflationary pressures of 2021-2023 were not a temporary disturbance but a structural realignment. That acknowledgment came late and under political pressure, and it raises a question the administration has shown little interest in asking: what does it mean that the premier technical institution in American economic life got the call so badly wrong?
The answer the current administration offers is that the institution itself was the problem. Not corruption, not inadequate data, not genuinely difficult forecasting — but the bureaucratic mindset that attaches itself to expert consensus and resists revision. And so the responses have been analogous: deregulate where possible, sideline where necessary, and create parallel structures that do not answer to the same professional norms.
The CBOE's extension of pre-market and post-market trading sessions, approved by the Securities and Exchange Commission and reported by Unusual Whales on 30 May 2026, is a granular but telling example. The pre-market session will now run from 7:30 a.m. ET to 9:25 a.m. ET, and the post-market session from 4:00 p.m. ET to 4:15 p.m. ET. The practical effect is marginal — institutional traders have always had after-hours access, and the liquidity available in these extended windows is thin by comparison with normal session trading. But the symbolic logic matters more than the financial logic. Extended hours are a statement that the market's operating calendar should expand to accommodate more activity, more friction, more opportunity. They are also, implicitly, a statement that the exchange infrastructure should be tuned to the demands of algorithmic trading rather than the rhythms of human market-making.
Oil markets, meanwhile, delivered their own verdict on the administration's early postures. According to CryptoBriefing, citing commodity reporting, oil prices experienced their largest monthly drop in six years during May 2026, falling approximately 20 percent in a single month. The causes are multiple — a softening Chinese demand picture, rising non-OPEC supply, and an OPEC+ coalition that has shown limited ability to hold production targets. But the trajectory aligns with a longer view that the administration has hinted at: a willingness to absorb short-term price disruption in exchange for a restructured energy relationship with Saudi Arabia and the broader Gulf states. The question of whether that restructuring is in the pipeline — and what terms it might involve — remains unaddressed in the public record. The sources do not specify the administration's private calculations on energy pricing, and speculation would be irresponsible. What is observable is the outcome: a market that is not behaving as the administration's allies in the Gulf would prefer.
These four threads — Lyme disease, inflation policy, extended trading hours, and oil price collapse — do not share a single cause. But they share a pattern. In each case, the administration has arrived with a diagnosis that points to institutional failure: the CDC missed chronic Lyme, the Fed misread inflation, the SEC constrains market access, OPEC manipulates prices. The prescribed remedy in each case is not incremental reform but structural displacement — the replacement of established process with something faster, flatter, and more directly accountable to political direction.
That diagnosis is not always wrong. The Fed's transitory inflation call did fail, and the consequences were felt in real household budgets. Chronic Lyme patients have documented genuine gaps in care and genuine skepticism from mainstream practitioners. Extended trading hours do, in theory, democratize access for smaller participants who cannot afford the infrastructure of after-hours trading. None of these failures are imaginary. The question is whether the cure — a systematic distrust of professional institutions, a preference for political over technical solutions — is proportionate to the disease.
The counterargument, which administration allies make with some consistency, is that professional institutions have become self-protective cliques whose primary function is the reproduction of their own authority. The Fed's "transitory" call, in this reading, was not a forecasting failure but a symptom of groupthink — an unwillingness to revise a model that had served the institution's professional culture even as real-world conditions diverged from it. The CDC's resistance to chronic Lyme, similarly, reflects a gatekeeping instinct that protects established research paradigms over patient experience. The SEC, by this logic, is an obstacle to market efficiency that benefits incumbents over new entrants.
That critique has real force. But it also has a dangerous sibling: the idea that political direction is inherently more legitimate than technical expertise, because it carries democratic accountability that experts can deflect with jargon. The administration has not, in most cases, built better institutions. It has, in several cases, simply dismantled the old ones — and left the space to be filled by whoever moves fastest, or whoever has the most direct line to the White House.
The oil market's 20 percent May collapse is the most immediate example of what happens when that space fills on its own terms. Saudi Arabia and its OPEC+ partners have responded to the price pressure with the tools they have — production adjustments, diplomatic signaling, the occasional public statement about supply discipline. But the underlying pressure on prices reflects structural forces that no individual producer can fully control: the continued growth of US shale output, the steady expansion of Brazilian and Guyana crude, and a Chinese industrial economy that is growing more slowly than a decade of projections assumed. The administration did not cause these forces. But its approach to diplomacy — transactional, transactional, and oriented toward bilateral deals rather than multilateral frameworks — has left it without the institutional relationships that might have softened the impact.
The Lyme disease agenda faces a different version of the same challenge. Kennedy's proposed reforms involve a significant redistribution of research funding and clinical authority — moving both away from NIH-based academic medicine and toward a network of practitioners and advocates who have operated outside the mainstream. Some of those practitioners have produced important work that the mainstream ignored. But others have promoted treatments that peer-reviewed evidence has found ineffective or harmful. The sources do not specify which network Kennedy's team is relying on, and the proposal remains under development. What is clear is that the structural intent — to bypass the institutions that have historically managed public health research — mirrors the approach visible in trade policy, in financial regulation, and in energy diplomacy.
What the administration is betting on, in every domain, is that speed and political will can substitute for institutional depth. That the frameworks that exist — the peer review process, the Fed's independence, the SEC's investor-protection mandate — are not features of a functioning democracy but obstacles to it. That bet may pay off in specific cases. A Lyme treatment breakthrough would vindicate the approach across the board. A successful renegotiation of Saudi oil terms would make the oil price collapse a footnote. But the pattern across these four cases is not one of targeted reform. It is one of systematic displacement, premised on the conviction that the people currently running the institutions are the problem, and that the solution is to sideline them.
The evidence from markets, from public health, and from geopolitical energy politics suggests that institutions do not fail only because of bad people. They fail because complex systems resist simple interventions, because expertise is acquired slowly and lost quickly, and because the political incentives that drive the displacement are different from the technical incentives that drive the work those institutions were built to do. The administration has diagnosed the problem correctly in several instances. The question is whether the treatment it has chosen — in all four cases simultaneously — is proportionate, or whether it reflects a more fundamental conviction that expertise itself is the problem to be solved.
The sources do not settle that question. What they establish is that the bet is being placed, across multiple domains, at the same time. And that its outcome will be determined not by the quality of the diagnosis but by the resilience of the systems being disrupted.
This publication covered the RFK Jr. Lyme disease proposal and the CBOE trading-hours expansion through the lens of regulatory philosophy rather than as isolated policy items. The Epoch Times framing emphasized bureaucratic streamlining; the wire framed the SEC extension as a technical market-infrastructure change. Both framings obscured the political logic that connects them — and to the oil market's 20 percent May collapse, and to the Fed's apparent revision of its inflation framework. The common thread is not policy coherence. It is institutional distrust as governing philosophy.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- https://www.cdc.gov/lyme/data-research/facts-stats/index.html